Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Justa & Lars Honors Bob Brinker Investment Club -- Ignore unavailable to you. Want to Upgrade?

To: marc ultra who wrote (11306)	1/19/2000 1:25:00 PM
From: Boca_PETE	Respond to of 15132

marc u: Thanks for the sentiment :-) P

To: marc ultra who wrote (11306)	1/19/2000 1:55:00 PM
From: marc ultra	Respond to of 15132

OT Interesting biotech to watch, not a recommendation to buy particularly ENMD which I mentioned before has now doubled since early December. They currently have Endostatin in Phase 1 clinical trials. As you may recall this was the drug that was the subject of a front page article in the Sunday NYT in April 98 I believe, noting its apparent ability to render cancerous tumors dormant and potentially cured in mice. Also the combination of endostain and angiostatin, one of the other drugs ENMD is developing and should be starting human trials shortly, seemed to have the ability to cure cancer in mice. Much controversy and a roller coaster ride since then as BMY, a partner in angiostatin dropped its participation due to a failed attempt to make stable angiostatin and a rather vicious WSJ article attacking the integrity of Judah Folkman who pioneered this strategy of angiogenesis inhibition to attack cancer by going after the blood vessels tumors sprout to get nutrients to grow and survive. There are currently many drugs from many companies in human trials using this strategy. The indications I get from the current Endostatin trial are that no toxicity has been seen and doses are being escalated but it is a little early and no clearly reliable information of significant efficacy yet which may be seen as doses are further increased. Endostatin might also have postential in cardiovascular disease which was the subject of a research agreement yesterday. Bottom line in the next several months there is a chance Endostatin could give initial indications that it could be the best cancer drug yet but it is much too early and bears watching both as a stock and what could be one of the biggest medical stories ever if results in humans come close to results in mice Also I should note that after BMY failed to take ENMD's advice on method of production and gave up on angiostatin, ENMD has successfully made human angiostatin to get ready for human trials which are likely to start shortly Marc

To: marc ultra who wrote (11306)	1/19/2000 2:50:00 PM
From: Wally Mastroly	Read Replies (1) \| Respond to of 15132

Marc, Re: sentiment - food for thought from the Brinker Web site discussion: bobbrinker.com - An excerpt: "..Right now, the speculation frenzy is at such a pitch that there isn't anything that is going to discourage participation. Valuation models have been thrown out the window and even a yield of 7% on the 30 year (bond) isn't going to make a lasting difference in sentiment..."

To: marc ultra who wrote (11306)	1/22/2000 12:42:00 AM
From: marc ultra	Read Replies (1) \| Respond to of 15132

Overall so far so good in my case since the TAA(tactical asset allocation) was called. Yes I had some of the same stocks that ran away after I sold like TER and NVLS not to speak of AAPL but most I got out of at pretty decent prices. Luckily I stuck to my decision to short SPY so as to comfortably hedge my funds which have run up and have a slight profit in my short position. It will be interesting to see how this all plays out but staying away from shorting the NASDAQ has so far been the right move and I hope those who did are at least getting appreciation on the stocks hedged against. Actually the reason why I am pretty happy at the moment is my one biotech ENMD that I mentioned again a few days ago here was up 22 points or 61% for the week following a good gain the week before and since this was my largest stock holding it's now way over 10% of my equities so a blow up will be painful. While the early stage endostatin cancer drug trials are under a shroud of secrecy the rumors and innuendoes I'm hearing raise a possibility something good is starting to happen but I have no direct knowledge or a source to really know what is going on. At least all reports agree no toxicity has been seen and we are now at a dose where efficacy might be expected extrapolating from mice data. No official announcements are expected for a very long time so it will be interesting to see what might happen in the interim. While it is technically in a Phase 1 safety study numerous tests are being done looking for possible tumor responses. I would not be surprised that if Bob's market concerns bear out we might suddenly get some big down days of many hundred points sometime in the near future. After all a 20% correction off the Dow highs is a drop of over 2300 points. Mondays are always the preferred day for such things for some reason so a real correction that includes the S&P and NASDAQ perhaps is not far off. Marc